Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Melanoma: HELP
Axel Hoos
Based on 18 articles published since 2009
(Why 18 articles?)
||||
Expertise Level
The expertise of Axel Hoos ranks in the
  • Top 0.53%
  • ... of 106,334 published authors worldwide on Melanoma
  • ... from 2009 through 2019
  • ... based on contributions to 18 articles on the topic.
Graphical view (beta)
Get your prestigious
Expert badge
similar to this:
 
Aliases Hoos, Axel   ·   Hoos, A
Work Locations
Details
Most likely:    GlaxoSmithKline      
2018
  • F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA · Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA · Jean-Charles Soria, AstraZeneca, Gaithersburg, MD · Josep Tabernero, Universitat Autònoma de Barcelona, Barcelona, Spain · Thomas Powles, Queen Mary University of London, London, United Kingdom · David Smith, Compass Oncology, Vancouver, WA · Axel Hoos, GlaxoSmithKline, Collegeville, PA · Ulrich Beyer, Roche Innovation Center, Basel, Switzerland · and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY. · Pubmed 29341833
2015
  • GlaxoSmithKline, Collegeville, Pennsylvania. Cancer Immunotherapy Consortium, New York, New York. · Cancer Immunotherapy Consortium, New York, New York. Memorial Sloan Kettering Cancer Center, New York, New York. · CytomX, San Francisco, California. · Dana-Farber Cancer Institute, Boston, Massachusetts. · Pubmed 26567357
  • California Pacific Center for Melanoma Research and Treatment, San Francisco, CA, USA. · Division of Hematology-Oncology, Vanderbilt University, Nashville, TN, USA. · Department of Medicine, Memorial-Sloan Cancer Institute, New York, NY, USA. · Oncology Research and Development, Glaxo Smith Kline, Collegeville, PA, USA. · Pubmed 25996827
Probable:    Bristol-Myers Squibb      
2015
  • Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. Electronic address: · IOV-IRCCS, Melanoma Oncology Unit, Padova, Italy. · Aix-Marseille University, Hôpital de La Timone APHM, Marseille, France. · University of Zürich Hospital, Zürich, Switzerland. · Memorial Sloan-Kettering Cancer Center, New York, NY, USA. · Aarhus University Hospital, Aarhus, Denmark. · The Angeles Clinic and Research Institute, Los Angeles, CA, USA. · Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. · Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy. · Oncology Specialists SC, Park Ridge, IL, USA. · Assistance Publique Hôpitaux de Paris, Dermatology and CIC Departments, Hôpital Saint Louis, University Paris 7, INSERM U976, France. · Istituti Fisioterapici Ospitalieri, Rome, Italy. · Cross Cancer Institute, Edmonton, Alberta, Canada. · H Lee Moffitt Cancer Center, Tampa, FL, USA. · University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. · Bristol-Myers Squibb, Wallingford, CT, USA. · Bristol-Myers Squibb, Braine-l'Alleud, Belgium. · EORTC Headquarters, Brussels, Belgium. · European Institute of Oncology, Milan, Italy. · Pubmed 25840693
2010
  • Global Clinical Research, Oncology, Bristol-Myers Squibb Co, Wallingford, CT 06492, USA. · Pubmed 21074069
Show More
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 18 total) written by Axel Hoos about Melanoma:

  • Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. 2018
  • Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. 2015
  • CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology. 2015
  • Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. 2015
  • Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. 2013
  • Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. 2012
  • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. 2011
  • Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma. 2011
  • Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. 2011
  • Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. 2010
Show List of Full Article Records
Google Searches

Learn more about Axel Hoos using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
GlaxoSmithKline
Bristol-Myers Squibb
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
GlaxoSmithKline
2018
  • F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA · Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA · Jean-Charles Soria, AstraZeneca, Gaithersburg, MD · Josep Tabernero, Universitat Autònoma de Barcelona, Barcelona, Spain · Thomas Powles, Queen Mary University of London, London, United Kingdom · David Smith, Compass Oncology, Vancouver, WA · Axel Hoos, GlaxoSmithKline, Collegeville, PA · Ulrich Beyer, Roche Innovation Center, Basel, Switzerland · and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY. · Pubmed 29341833
2015
  • GlaxoSmithKline, Collegeville, Pennsylvania. Cancer Immunotherapy Consortium, New York, New York. · Cancer Immunotherapy Consortium, New York, New York. Memorial Sloan Kettering Cancer Center, New York, New York. · CytomX, San Francisco, California. · Dana-Farber Cancer Institute, Boston, Massachusetts. · Pubmed 26567357
  • California Pacific Center for Melanoma Research and Treatment, San Francisco, CA, USA. · Division of Hematology-Oncology, Vanderbilt University, Nashville, TN, USA. · Department of Medicine, Memorial-Sloan Cancer Institute, New York, NY, USA. · Oncology Research and Development, Glaxo Smith Kline, Collegeville, PA, USA. · Pubmed 25996827
Bristol-Myers Squibb
2015
  • Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. Electronic address: · IOV-IRCCS, Melanoma Oncology Unit, Padova, Italy. · Aix-Marseille University, Hôpital de La Timone APHM, Marseille, France. · University of Zürich Hospital, Zürich, Switzerland. · Memorial Sloan-Kettering Cancer Center, New York, NY, USA. · Aarhus University Hospital, Aarhus, Denmark. · The Angeles Clinic and Research Institute, Los Angeles, CA, USA. · Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. · Istituto Nazionale Tumori Fondazione G Pascale, Naples, Italy. · Oncology Specialists SC, Park Ridge, IL, USA. · Assistance Publique Hôpitaux de Paris, Dermatology and CIC Departments, Hôpital Saint Louis, University Paris 7, INSERM U976, France. · Istituti Fisioterapici Ospitalieri, Rome, Italy. · Cross Cancer Institute, Edmonton, Alberta, Canada. · H Lee Moffitt Cancer Center, Tampa, FL, USA. · University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy. · Bristol-Myers Squibb, Wallingford, CT, USA. · Bristol-Myers Squibb, Braine-l'Alleud, Belgium. · EORTC Headquarters, Brussels, Belgium. · European Institute of Oncology, Milan, Italy. · Pubmed 25840693
2010
  • Global Clinical Research, Oncology, Bristol-Myers Squibb Co, Wallingford, CT 06492, USA. · Pubmed 21074069
12 Other Locations Show
Yearly article counts 01003011363
 
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.